Dengue virus envelope protein serotype 3 (DENV-3 E protein)

The Dengue virus envelope protein serotype 3 is a ~53 kDa glycoprotein that forms head-to-tail dimers on the surface of the DENV-3 virion, providing the structural matrix of the viral capsid along with capsid protein. It comprises three domains: Domain I, a β-barrel; Domain II, containing the fusion peptide for host membrane fusion; and Domain III, an immunoglobulin-like fold responsible for receptor binding and major antigenic specificity. Domain III of the envelope protein is a central target for neutralizing antibodies and forms the basis for diagnostic and vaccine development. This protein is essential for both host cell entry and eliciting serotype-specific and cross-reactive immune responses. DENV-3 E protein’s structure and epitopes are highly conserved, yet domain III shows key variability that allows for both broad and serotype-specific immune responses, rendering it crucial for both disease pathogenesis and therapeutic intervention.

Other names

Dengue virus serotype 3 envelope proteinDENV3 envelope glycoproteinDENV-3 E proteinE glycoprotein (DENV-3)

Neutralizing antibodies block receptor binding or fusion, preventing viral entry into host cells. Some interventions aim to elicit serotype-specific or cross-reactive antibody responses. Engineered envelope antigens can direct immune response to critical neutralizing epitopes with reduced risk of antibody-dependent enhancement (ADE).